Lessons from $800-million drug flop may lead to a new genre of anti-cholesterol medicines
Mindful of lessons from a failed heart drug that cost $800 million to develop, drug companies are taking another shot at new medications that boost levels of so-called "good cholesterol," which removes cholesterol from the body. A report on how three new versions of medications in the same family as the failed torcetrapib appears in the current edition of Chemical & Engineering News, the newsmagazine of the American Chemical Society, the world's largest scientific society.
In the cover story, C&EN Associate Editor Carmen Drahl explains that the drug maker Pfizer abruptly ...
